Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CardioDynamics Posts Net Sales Of $5.1 Million For Q1 2009, Down 12%
ICG sensor revenue increased 12% to $1.7 million, representing 33% of net sales, up from $1.5 million, or 26% of sales Gross margin as a percentage of net
ICG sensor revenue increased 12% to $1.7 million, representing 33% of net sales, up from $1.5 million, or 26% of sales Gross margin as a percentage of net
Most recently Archimbaud served as senior vice president, life sciences for the Societe Generale de Financement (SGF) du Quebec, a government-owned investment entity contributing to the development of
Microsoft Dynamics AX 2009 will be the foundation for billing, accounting, human resources, and materials management applications that integrate with the clinical, patient administration, and financial capabilities in
Clinical Data, a biotechnology company, and Beckman Coulter, a developer of biomedical tests, have signed a definitive agreement, pursuant to which, Beckman Coulter will acquire Clinical Data’s Cogenics
Aplenzin differs from other generic and branded bupropion antidepressants because it provides a unique HBr salt extended-release formulation, offering prescribers and their patients the benefit of convenience with
The product label provides that one 8mg Rapaflo capsule be taken once daily with a meal. Stocking efforts have ensured the product will be available immediately by prescription
Under the new labeling, the agency allows physicians to treat up to 100% of the fibroid compared to its previous restriction to only treat up to half the
Affitech, an antibody R&D company, has reported that the European Patent Office has granted a European patent on the use of phagemid particles having an antibody-coliphage pIII fusion
Efient is a new antiplatelet agent that was granted marketing authorization by the European Commission on February 25, 2009, for the reduction of atherothrombotic events in patients with
Michael McManus, Jr, president and CEO of Misonix, said: “We are pleased to further strengthen our balance sheet with the additional $3.5 million in cash from the sale